Pharmaceutical guidance for optimizing the use of asthma medications
- Conditions
- AsthmaTreatment Adherence and Compliance
- Registration Number
- RBR-9kkjvnj
- Lead Sponsor
- niversidade Federal do Rio Grande do Norte
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Both sexes. Aged 18 years or older. Confirmed diagnosis of Asthma through spirometry. Patients currently using or starting the use of a dry powder inhaler (Aerolizer, Turbuhaler) and/or inhalation solution (Respimat system) on D0. Informed and voluntary consent to participate in the clinical trial
Conditions that may influence the learning of the inhalation technique (psychiatric, neurological, or rheumatological disorders). Presence of respiratory diseases other than asthma. Ongoing viral or bacterial respiratory infection. Dependency on third parties for DI handling. Hearing impairment. Severe visual impairment. Treatment with a different DI other than Aerolizer, Turbuhaler, and Respimat. Active smoking. Undergoing respiratory physiotherapy
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method